154 related articles for article (PubMed ID: 8840240)
1. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.
Yamada M; Fukuda Y; Koyama Y; Nakano I; Urano F; Katano Y; Hayakawa T
J Gastroenterol Hepatol; 1996 Jul; 11(7):646-51. PubMed ID: 8840240
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system.
Ninomiya T; Yoon S; Hayashi Y; Sugano M; Kumon Y; Seo Y; Shimizu K; Kasuga M
J Gastroenterol Hepatol; 1998 Jan; 13(1):68-74. PubMed ID: 9737575
[TBL] [Abstract][Full Text] [Related]
3. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C.
Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagasawa M; Toyama T; Ozaki S; Naito M; Azuma M
Hepatology; 1996 Jul; 24(1):27-31. PubMed ID: 8707274
[TBL] [Abstract][Full Text] [Related]
4. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection.
Zöhrens G; Armbrust T; Meyer Zum Büschenfelde KH; Ramadori G
Dig Dis Sci; 1994 Sep; 39(9):2007-13. PubMed ID: 8082511
[TBL] [Abstract][Full Text] [Related]
6. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease.
Yamada M; Fukuda Y; Nakano I; Katano Y; Takamatsu J; Hayakawa T
Acta Haematol; 1998; 99(4):212-6. PubMed ID: 9644299
[TBL] [Abstract][Full Text] [Related]
7. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.
Hiramatsu N; Hayashi N; Kasahara A; Hagiwara H; Takehara T; Haruna Y; Naito M; Fusamoto H; Kamada T
J Hepatol; 1995 Feb; 22(2):135-42. PubMed ID: 7790701
[TBL] [Abstract][Full Text] [Related]
8. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
[TBL] [Abstract][Full Text] [Related]
9. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.
Gallorini A; Plebani M; Pontisso P; Chemello L; Masiero M; Mantovani G; Alberti A
Liver; 1994 Oct; 14(5):257-64. PubMed ID: 7997085
[TBL] [Abstract][Full Text] [Related]
10. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
[TBL] [Abstract][Full Text] [Related]
11. [Serum markers and pathological evaluation in hepatitis fibrosis of chronic hepatitis B treated with interferon alpha].
Deng L; Zhou Y; Peng X; Deng H; Deng Y; Yao J
Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():66-7. PubMed ID: 11509145
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis.
Guéchot J; Laudat A; Loria A; Serfaty L; Poupon R; Giboudeau J
Clin Chem; 1996 Apr; 42(4):558-63. PubMed ID: 8605673
[TBL] [Abstract][Full Text] [Related]
13. Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon.
Kojima H; Hongo Y; Harada H; Inoue T; Miyaji K; Kashiwagi M; Momose T; Arisaka Y; Fukui H; Murai S; Tokita H; Kamitsukasa H; Yagura M; Katsu K
J Gastroenterol Hepatol; 2001 Sep; 16(9):1015-21. PubMed ID: 11595066
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of serum markers with fibrosis staging in chronic viral hepatitis].
Wang T; Wang B; Liu X
Zhonghua Bing Li Xue Za Zhi; 1998 Jun; 27(3):185-90. PubMed ID: 11244978
[TBL] [Abstract][Full Text] [Related]
16. Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease.
Mazzoran L; Tamaro G; Mangiarotti MA; Marchi P; Baracetti S; Gerini U; Fanni-Cannelles M; Zorat F; Pozzato G
Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):125-31. PubMed ID: 9581987
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C.
Patel K; Lajoie A; Heaton S; Pianko S; Behling CA; Bylund D; Pockros PJ; Blatt LM; Conrad A; McHutchison JG
J Gastroenterol Hepatol; 2003 Mar; 18(3):253-7. PubMed ID: 12603524
[TBL] [Abstract][Full Text] [Related]
18. Serum markers of liver fibrosis and histologic severity of fibrosis in resected liver.
Tsukamoto T; Yamamoto T; Ikebe T; Takemura S; Shuto T; Kubo S; Hirohashi K; Kinoshita H
Hepatogastroenterology; 2004; 51(57):777-80. PubMed ID: 15143915
[TBL] [Abstract][Full Text] [Related]
19. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C.
Guéchot J; Poupon RE; Giral P; Balkau B; Giboudeau J; Poupon R
J Hepatol; 1994 Mar; 20(3):388-93. PubMed ID: 8014451
[TBL] [Abstract][Full Text] [Related]
20. Serum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy.
Shimizu I; Omoya T; Takaoka T; Wada S; Wada H; Taoka M; Hayashi H; Hayashi S; Honda H; Sano N; Ito S
J Gastroenterol Hepatol; 2001 Feb; 16(2):196-201. PubMed ID: 11207901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
